January 30, 2023
AmMax Bio Announces First Patients Dosed in Phase 2b Study of...
REDWOOD CITY, Calif. January 30, 2023 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
November 18, 2022
AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X...
REDWOOD CITY, Calif. Nov 18, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
September 7, 2022
AmMax Bio Announces AMB-05X Granted FDA Fast Track Designation...
REDWOOD CITY, Calif. Sep 7, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
February 24, 2022
AmMax Bio Announces the Appointment of Biotechnology...
REDWOOD CITY, Calif. February 24, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
October 20, 2021
AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X...
RREDWOOD CITY, Calif. October 20, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing ...
April 29, 2021
AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare...
RREDWOOD CITY, Calif. Apr. 29, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
March 30, 2020
LifeMax Launches AmMax Bio Following The License Of Worldwide Rights...
Redwood City, California – (Business Wire) – March 30, 2020 – LifeMax Laboratories, Inc. (“LifeMax”), a private company ...
January 19, 2023
AmMax Bio’s AMB-05X Receives EMA PRIME Designation for...
REDWOOD CITY, Calif. January 19, 2023 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
September 26, 2022
AmMax Bio Provides Update on AMB-05X Program for...
REDWOOD CITY, Calif. Sep 26, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
July 25, 2022
AmMax Bio Announces the Appointment of Dorothy Nguyen, M.D. as...
REDWOOD CITY, Calif. July 25, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
December 7, 2021
KOL Webinar REPLAY: Forging a New Standard of care in TCGT
The webinar featured presentations by two tenosynovial giant cell tumor experts from Leiden University Medical Center.
July 14, 2021
AmMax Bio to Present at the 2nd Annual LifeSci Partners Private...
RREDWOOD CITY, Calif. July 14, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
March 2, 2021
AmMax Bio Announces the Appointment of Biotechnology Executive...
REDWOOD CITY, Calif. March 2, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
January 09, 2023
AmMax Bio Enters into an Exclusive Option Agreement with...
REDWOOD CITY, Calif. and Suzhou, China, January 09, 2023 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage ...
September 12, 2022
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of...
REDWOOD CITY, Calif. Sep 12, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
March 2, 2022
AmMax Bio Announces Positive Phase 2 Results Demonstrating...
REDWOOD CITY, Calif. March 2, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
November 30, 2021
AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for the...
REDWOOD CITY, Calif. Nov 30, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing ...
May 26, 2021
AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of AMB-05X...
RREDWOOD CITY, Calif. May 26, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...
February 16, 2021
AmMax Bio to Participate in the 41st Annual Cowen Health Care Conference
REDWOOD CITY, Calif. February 16, 2021 — AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company ...